Literature DB >> 8853194

Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent.

L Martinet1, B Guardiola-Lemaitre, E Mocaer.   

Abstract

The present study determined first the dose-response (0.5 to 10 mg.kg-1) to daily oral administration of S-20098, a melatonin agonist, in entraining circadian rhythms of rats free-running in constant darkness; second, the relation between entrainment and the plasma concentration of S-20098. Finally, responses to 8 mg.kg-1 of S-20098 were compared with those obtained with the same dose of melatonin and ipsapirone. Responses were classified as negative, transient, or true entrainment. The data indicated a clear dose-dependent response from 2.5 to 10 mg.kg-1 of S-20098 with an ED50 of 5.7 mg.kg-1 for true entrainment and a clear relation between entrainment and the plasma concentration of S-20098. S-20098 was as effective as melatonin to entrain free-running rhythms. Ipsapirone was ineffective in our experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853194     DOI: 10.1016/0091-3057(95)02221-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  16 in total

Review 1.  Depression research: where are we now?

Authors:  Saebom Lee; Jaehoon Jeong; Yongdo Kwak; Sang Ki Park
Journal:  Mol Brain       Date:  2010-03-10       Impact factor: 4.041

Review 2.  Circadian rhythm disturbances in depression.

Authors:  Anne Germain; David J Kupfer
Journal:  Hum Psychopharmacol       Date:  2008-10       Impact factor: 1.672

3.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

4.  Agomelatine: protecting the CNS from the effects of stress.

Authors:  Stefania Maccari; Ferdinando Nicoletti
Journal:  CNS Neurosci Ther       Date:  2011-10       Impact factor: 5.243

Review 5.  Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.

Authors:  Christian de Bodinat; Béatrice Guardiola-Lemaitre; Elisabeth Mocaër; Pierre Renard; Carmen Muñoz; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2010-06-25       Impact factor: 84.694

6.  Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.

Authors:  Michel Bourin; Elisabeth Mocaër; Roger Porsolt
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

Review 7.  Agomelatine: innovative pharmacological approach in depression.

Authors:  Maurizio Popoli
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 8.  Agomelatine: a preliminary review of a new antidepressant.

Authors:  Michael Zupancic; Christian Guilleminault
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.

Authors:  Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Journal:  Psychopharmacology (Berl)       Date:  2009-04-16       Impact factor: 4.530

10.  Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.

Authors:  Abdeslam Chagraoui; Philippe Protais; Thierry Filloux; Elisabeth Mocaër
Journal:  Psychopharmacology (Berl)       Date:  2003-08-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.